Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Folia Histochem Cytobiol ; 60(4): 335-343, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36583336

RESUMO

INTRODUCTION: Aberrant fucosylation is closely related to malignant transformation, cancer detection, and evaluation of treatment efficacy. The fucosylation process requires GDP-L-fucose, fucosyltransferases, and fucosidases. In gastric cancer (GC), fucosylation alterations were associated with tumor formation, metastasis inhibition, and multi-drug resistance. It is not clear whether tissue-specific transplantation antigen P35B (TSTA3) and alpha-L-fucosidase 2 (FUCA2) have any effect on the development of GC. MATERIALS AND METHODS: We used immunohistochemistry to assess the expression of TSTA3 and FUCA2 in 71 gastric adenocarcinoma samples and their relationship with clinicopathological parameters. RESULTS: TSTA3 expression was associated with lower histological grade I and II (P = 0.0120) and intestinal type Lauren classification (P = 0.0120). TSTA3 immunopositivity could predict Lauren's classification. Analysis of mRNA expression in GC validation cohorts corroborates the significant TSTA3 association with histological grade observed in our study. However, no associations were found between TSTA3 staining and overall survival. FUCA2 expression was markedly increased in GC tissues compared with non-tumoral tissues (P < 0.0001) and was associated with surgical staging III and IV (P = 0.0417) and advanced histological grade tumor states (P = 0.0125). CONCLUSIONS: Alterations of FUCA2 and TSAT3 immunoexpression could lay the basis for future studies using cell glycosylation as a biomarker for the planning of therapeutic strategy in primary gastric cancer.


Assuntos
Adenocarcinoma , Cetona Oxirredutases , Neoplasias Gástricas , Humanos , alfa-L-Fucosidase/metabolismo , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/patologia , Adenocarcinoma/patologia , Biomarcadores , Biomarcadores Tumorais , Carboidratos Epimerases/genética , Carboidratos Epimerases/metabolismo , Cetona Oxirredutases/genética , Cetona Oxirredutases/metabolismo
2.
Dis Markers ; 2019: 6325326, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31827638

RESUMO

The UDP-glucose 4-epimerase (GALE) is a glycosyltransferase, which acts on protein and lipid glycosylation in normal and neoplastic cells. This study is aimed at investigating the differential tissue expression of GALE and its possible association with clinical-pathological parameters and the outcome of gastric adenocarcinoma patients. Seventy-one patients were evaluated in relation to GALE expression by immunohistochemistry. Our results showed that 48 (67.6%) patients were GALE positive and 23 (32.4%) negative. Positive staining was present on well-differentiated and moderate-differentiated histological grade of gastric adenocarcinomas (p < 0.0001). There was no significant association with outcome parameters (p > 0.05). Besides that, our results corroborated with the validation cohort analysis, where the expression of GALE mRNA was also associated with the histological grade (p < 0.001). These results suggest a possible use of this enzyme as a biomarker for well and moderately differentiated tumors.


Assuntos
Adenocarcinoma/secundário , Biomarcadores Tumorais/metabolismo , Recidiva Local de Neoplasia/patologia , Neoplasias Gástricas/patologia , UDPglucose 4-Epimerase/metabolismo , Adenocarcinoma/metabolismo , Adenocarcinoma/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Diferenciação Celular , Terapia Combinada , Feminino , Seguimentos , Humanos , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Gradação de Tumores , Recidiva Local de Neoplasia/metabolismo , Recidiva Local de Neoplasia/terapia , Neoplasias Gástricas/metabolismo , Neoplasias Gástricas/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...